Skip to content

SARS-CoV-2 Infection Among Healthcare Workers

The Risk of SARS-CoV-2 Infection and Severity of COVID-19 Among Healthcare Workers With or Without Previous COVID-19 Vaccines

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05680896
Enrollment
600
Registered
2023-01-11
Start date
2023-02-01
Completion date
2024-12-22
Last updated
2023-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Brief summary

At present, COVID-19 vaccine is considered as the safest, economic and effective measure to prevent and control COVID-19. Adaptive immunity, including humoral immunity and cellular immunity, plays a role in anti-viral responses. Cellular immunity includes virus specific B cells and T cells, which can provide long-term memory immunity. For acute viral infection, neutralizing antibody is of great significance in preventing infection, while memory cell immunity can maintain a good broad-spectrum and persistence in controlling mutant strains, which is a key factor in controlling viral replication after infection and reducing severe disease and death. However, there is no systematic study on the specific immune response and infection risk of novel coronavirus, and there is no definite conclusion on which specific protective immune response induced by vaccine can reduce the risk of infection. Therefore, this study aims to establish a prospective real-world cohort, analyze the correlation between multiple baseline immune protection indicators and infection risk, follow up the population with breakthrough infection, and monitor the dynamic specific immune response to COVID-19 in peripheral blood and respiratory mucosa. This study will provide an important scientific basis for us to scientifically assess the risk of individual infection with COVID-19.

Interventions

BIOLOGICALinactivated COVID-19 vaccines; orally aerosolized Ad5-nCoV

the protection of COVID-19 vaccines on breakthrough infection

Sponsors

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

1. Age ≥18 years 2. SARS-CoV-2 nucleic acid testing showed negative within 72 hours

Exclusion criteria

1.Do not consent to enroll in this study

Design outcomes

Primary

MeasureTime frameDescription
SARS-CoV-2 infectionfrom Dec 2022 to April 2023SARS-CoV-2 infection confirmed by either by nucleic acid testing or antigen testing
The severity of COVID-19from Dec 2022 to April 2023the severity of COVID-19 symptoms including the period from SARS-CoV-2 positive to negative, fever days, etc.

Countries

China

Contacts

Primary ContactChao Wu, PhD
dr.wu@nju.edu.cn+8613809022921
Backup ContactYuxin Chen, PhD
yuxin.chen@nju.edu.cn+8617714413628

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 6, 2026